App-Quantinova.ai

The extent and characteristics of diagnostic delay in axSpA: a systematic review

Charles A Hay - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Comparative effects of ixekizumab (IXE) vs adalimumab (ADA) across PsA patients defined by baseline characteristics: week 24 outcomes from SPIRIT-H2H

Hasan Tahir - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Dactylitis

Adalimumab

Assessment of disease activity using RAPID3 and evaluation of treatment effect of guselkumab in patients with PsA: results from a randomised placebo-controlled Phase 2 clinical trial

Atul Deodhar - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

Ustekinumab

Real-world experience with an IL-17A blocker in biologic-naïve and biologic-experienced radiographic and non-radiographic axSpA patients

Nicola Booth - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

secukinumab

Guselkumab was more effective than secukinumab in patients with plaque psoriasis and the subset of patients with self-reported PsA in the randomised, double-blind, head-to-head comparison study ECLIPSE over 1 year

Joseph F Merola - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

secukinumab

Clinical burden of concomitant joint disease in psoriasis: a US-linked claims and electronic medical records database analysis

William Tillett - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Depression

N/A

52-Week efficacy and safety of ixekizumab in r-axSpA/AS patients naïve to biologic treatments or with prior inadequate response/intolerance to tumor necrosis factor inhibitors

Karl Gaffney - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

LY2439821

Outcome for PsA biologic switchers following primary inefficacy of TNFi therapy in a secondary care cohort: sequential TNFi versus switching mode of action

Meena Naja - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Clinical predictors of switching biologic treatment in patients PsA: data from a single centre over 17 years

Meena Naja - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Certolizumab pegol-treated patients with non-radiographic axSpA demonstrate improvements in sleep quality and other patient reported outcomes

Raj Sengupta - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

Certolizumab pegol

Using FITBITR for fitness monitoring in patients attending the AS residential course at RNHRD: it does make a difference!

Muhammad Safwan Jamal - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Gastric antral vascular ectasia

N/A

Examining the relationships between important other autonomy support, basic psychological need satisfaction and well-being in those with non-radiographic AxSpA

Thomas A Ingram - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

N/A

Audit of the monitoring and documentation of DAS28 score in patients prescribed high cost DMARDs for rheumatoid arthritis every 6 months according to British Society for Rheumatology guidelines

Kevin F. W Tsoi - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

How much time do we spend seeing non-inflammatory conditions? A district general hospital’s perspective

Matthew J Saunders - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

N/A

An audit of glucocorticoid prescription in patients with giant cell arteritis

Hairul Hadi Ariff - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Giant cell arteritis

Glucocorticoid

Hypercalcaemia of sarcoidosis in a patient with severe renal impairment successfully treated with denosumab

Randa Alshakh - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Nonalcoholic fatty liver disease

Parathyroid hormone

The wolf finds unusual prey

Mithun Chakravorty - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Obstructive uropathy

N/A

Successful treatment of alopecia universalis with rituximab therapy

Anuoluwapo R Oke - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Antisynthetase Syndrome

Cyclophosphamide

Synovitis-acne-pustulosis-hyperostosis-osteitis syndrome: diagnosis via chest radiograph

Lavanya Anandan - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Acne

N/A

Bamboo nodes in a patient with mixed connective tissue disease

Dimitrios C Christidis - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Filters

45280 Abstracts